1. Home
  2. INZY vs QBTS Comparison

INZY vs QBTS Comparison

Compare INZY & QBTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INZY
  • QBTS
  • Stock Information
  • Founded
  • INZY 2015
  • QBTS 1999
  • Country
  • INZY United States
  • QBTS Canada
  • Employees
  • INZY N/A
  • QBTS N/A
  • Industry
  • INZY Biotechnology: Pharmaceutical Preparations
  • QBTS Retail: Computer Software & Peripheral Equipment
  • Sector
  • INZY Health Care
  • QBTS Technology
  • Exchange
  • INZY Nasdaq
  • QBTS Nasdaq
  • Market Cap
  • INZY 188.2M
  • QBTS 194.5M
  • IPO Year
  • INZY 2020
  • QBTS N/A
  • Fundamental
  • Price
  • INZY $1.36
  • QBTS $6.24
  • Analyst Decision
  • INZY Strong Buy
  • QBTS Strong Buy
  • Analyst Count
  • INZY 8
  • QBTS 6
  • Target Price
  • INZY $17.75
  • QBTS $6.38
  • AVG Volume (30 Days)
  • INZY 677.5K
  • QBTS 111.3M
  • Earning Date
  • INZY 11-05-2024
  • QBTS 11-14-2024
  • Dividend Yield
  • INZY N/A
  • QBTS N/A
  • EPS Growth
  • INZY N/A
  • QBTS N/A
  • EPS
  • INZY N/A
  • QBTS N/A
  • Revenue
  • INZY N/A
  • QBTS $9,424,000.00
  • Revenue This Year
  • INZY N/A
  • QBTS $4.94
  • Revenue Next Year
  • INZY N/A
  • QBTS $63.93
  • P/E Ratio
  • INZY N/A
  • QBTS N/A
  • Revenue Growth
  • INZY N/A
  • QBTS 14.27
  • 52 Week Low
  • INZY $1.38
  • QBTS $0.68
  • 52 Week High
  • INZY $7.80
  • QBTS $11.41
  • Technical
  • Relative Strength Index (RSI)
  • INZY 20.23
  • QBTS 49.31
  • Support Level
  • INZY $2.68
  • QBTS $3.74
  • Resistance Level
  • INZY $3.18
  • QBTS $6.35
  • Average True Range (ATR)
  • INZY 0.28
  • QBTS 1.46
  • MACD
  • INZY -0.15
  • QBTS -0.59
  • Stochastic Oscillator
  • INZY 1.88
  • QBTS 32.59

About INZY Inozyme Pharma Inc.

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

About QBTS D-Wave Quantum Inc.

D-Wave Quantum Inc is engaged in the development and delivery of quantum computing systems, software, and services, and is the commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. The Company's mission is to unlock the power of quantum computing today to benefit business and society. D-Wave does this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modelling. D-Wave's annealing quantum computers are accessible through the Company's LeapTM cloud service.

Share on Social Networks: